Price
Financials
Consolidated, Rs crore| Mar 2022 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 84.94 | 61.79 | 105.72 | 84.80 | 99.25 | 95.68 | 112.69 | 91.36 | 102.33 | 107.89 | 120.93 | 110.24 |
| Expenses | 40.61 | 38.91 | 75.48 | 66.04 | 73.94 | 66.04 | 75.67 | 66.66 | 74.88 | 76.37 | 86.66 | 84.25 |
| Operating Profit | 44.33 | 22.88 | 30.24 | 18.76 | 25.31 | 29.64 | 37.02 | 24.70 | 27.45 | 31.52 | 34.27 | 25.99 |
| OPM % | 52.19% | 37.03% | 28.60% | 22.12% | 25.50% | 30.98% | 32.85% | 27.04% | 26.82% | 29.21% | 28.34% | 23.58% |
| Other Income | 2.58 | 3.24 | 3.38 | 2.91 | 8.43 | 0.85 | 3.78 | 3.34 | 5.80 | 7.07 | 6.83 | 5.98 |
| Interest | 0.45 | 2.51 | 4.25 | 4.32 | 4.84 | 5.03 | 5.20 | 5.07 | 5.18 | 6.05 | 6.25 | 6.27 |
| Depreciation | 7.24 | 10.06 | 12.33 | 11.03 | 14.03 | 17.41 | 20.03 | 19.94 | 22.48 | 25.04 | 29.08 | 27.02 |
| Profit before tax | 39.22 | 13.55 | 17.04 | 6.32 | 14.87 | 8.05 | 15.57 | 3.03 | 5.59 | 7.50 | 5.77 | -1.32 |
| Tax % | 24.89% | 26.72% | 39.50% | 36.39% | 30.80% | 34.66% | 34.49% | 41.25% | 40.61% | 32.93% | 27.56% | 9.09% |
| Net Profit | 29.46 | 9.93 | 10.32 | 4.02 | 10.29 | 5.26 | 10.20 | 1.78 | 3.32 | 5.04 | 4.18 | -1.44 |
| EPS in Rs | 5.54 | 1.87 | 1.94 | 0.76 | 1.93 | 0.99 | 1.92 | 0.33 | 0.62 | 0.95 | 0.79 | -0.27 |
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 229 | 301 | 296 | 392 | 423 | 441 |
| Expenses | 125 | 148 | 196 | 282 | 304 | 322 |
| Operating Profit | 103 | 153 | 100 | 111 | 118 | 119 |
| OPM % | 45% | 51% | 34% | 28% | 28% | 27% |
| Other Income | 5 | 8 | 11 | 16 | 23 | 26 |
| Interest | 3 | 4 | 10 | 20 | 23 | 24 |
| Depreciation | 14 | 22 | 40 | 62 | 97 | 104 |
| Profit before tax | 92 | 135 | 61 | 45 | 22 | 18 |
| Tax % | 25% | 25% | 30% | 34% | 35% | |
| Net Profit | 69 | 101 | 43 | 30 | 14 | 11 |
| EPS in Rs | 3,583.25 | 18.92 | 8.01 | 5.60 | 2.69 | 2.09 |
| Dividend Payout % | 0% | 0% | 25% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 13% | % | 11% | ||
| Compounded Profit Growth | % | -26% | % | -57% | ||
| Stock Price CAGR | % | % | -14% | 7% | ||
| Return on Equity | % | % | 5% | 2% |
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.19 | 11 | 11 | 11 | 11 |
| Reserves | 244 | 479 | 602 | 620 | 624 |
| Borrowings | 34 | 22 | 269 | 339 | 393 |
| Other Liabilities | 18 | 33 | 90 | 111 | 158 |
| Total Liabilities | 296 | 544 | 972 | 1,080 | 1,186 |
| Fixed Assets | 120 | 189 | 336 | 536 | 733 |
| CWIP | 22 | 32 | 267 | 233 | 159 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 153 | 323 | 369 | 311 | 295 |
| Total Assets | 296 | 544 | 972 | 1,080 | 1,186 |
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity | 68 | 83 | 103 | 114 | 118 |
| Cash from Investing Activity | -64 | -138 | -285 | -145 | -129 |
| Cash from Financing Activity | -27 | 130 | 136 | 39 | 9 |
| Net Cash Flow | -23 | 75 | -47 | 8 | -2 |
| Free Cash Flow | 6 | -48 | -81 | -37 | -7 |
| CFO/OP | 89% | 77% | 121% | 117% | 107% |
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 75 | 79 | 96 | 74 | 74 |
| Inventory Days | 277 | 478 | 572 | 355 | 341 |
| Days Payable | 35 | 75 | 65 | 44 | 53 |
| Cash Conversion Cycle | 317 | 482 | 602 | 385 | 361 |
| Working Capital Days | 108 | 150 | -1 | 38 | -20 |
| ROCE % | 35% | 7% | 5% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 47.31% | 47.31% | 47.31% | 47.31% | 47.31% | 47.31% | 47.31% | 47.31% | 47.31% | 47.30% | 47.30% | 47.30% |
| FIIs | 7.85% | 6.83% | 8.16% | 7.95% | 8.04% | 7.51% | 9.53% | 9.14% | 5.82% | 2.46% | 0.87% | 0.15% |
| DIIs | 3.15% | 2.60% | 0.17% | 0.11% | 0.21% | 0.51% | 0.30% | 0.04% | 0.08% | 0.00% | 0.19% | 0.10% |
| Public | 41.68% | 43.27% | 44.36% | 44.63% | 44.45% | 44.69% | 42.89% | 43.50% | 46.79% | 50.23% | 51.65% | 52.44% |
| No. of Shareholders | 1,08,236 | 1,07,564 | 1,02,866 | 1,05,330 | 99,586 | 96,927 | 93,417 | 90,891 | 88,966 | 87,336 | 84,093 | 83,453 |
Fundamentals
Market Cap₹ 1,754 Cr.
Current Price₹ 330
Stock P/E148
Book Value₹ 119
ROCE4.59 %
ROE2.44 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)11%
Compounded Profit Growth (TTM)-57%
Consolidated figures.
Ownership
Promoter holding47.30% (-0.01 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | TARSONS | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -1.8% | -2.8% | +1.0 pts |
| 1 month | -4.3% | -6.8% | +2.5 pts |
| 3 months | +23.6% | -7.6% | +31.2 pts |
| 6 months | +97.9% | +0.4% | +97.5 pts |
| 1 year | +6.6% | -9.9% | +16.5 pts |
| 2 years | -30.0% | -13.6% | -16.4 pts |
| 3 years | -37.4% | +14.2% | -51.6 pts |
1 mutual fund schemes hold about ₹0 Cr.
Over three months 0 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund | 0.03% | 0 | -4% |
Red flags
| look | Auditor change Auditor change 2026-05-22: Tarsons Products Limited has informed the Exchange regarding Change in Auditors of the company. |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹110 Cr +20.7% vs Jun 2025.
Net loss ₹1 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Q-Line Biotech Ltd | 1,569 | 27.8 | 22.5 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Hemant Surgical Industries Ltd | 869 | 51.3 | 18.9 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| QMS Medical Allied Services Ltd | 419 | 39.0 | 12.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Aprameya Engineering Ltd | 200 | 39.7 | 12.6 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
| Vaidya Sane Ayurved Laboratories Ltd | 176 | 19.6 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2024-09-20 | Annual General Meeting/Dividend - Rs 2 Per Share | |
| 2023-07-07 | Annual General Meeting | |
| 2022-07-21 | Annual General Meeting |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 75perc in previous 6 monthsHigh low price variation greater than 100perc in previous 6 monthsScrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Tarsons Products Ltd?
Tarsons Products Ltd (TARSONS) has a market capitalisation of Rs 1,754 Cr. at the 2026-10-01 close.
What is the P/E ratio of Tarsons Products Ltd?
Tarsons Products Ltd trades at a P/E of 148 on trailing twelve-month profit, at the 2026-10-01 close.
What were Tarsons Products Ltd's latest quarterly results?
In the Jun 2026 quarter, Tarsons Products Ltd sales was Rs 110 Cr (+20.7% vs Jun 2025) with a net loss of Rs 1 Cr.
What is the 52-week high and low of Tarsons Products Ltd?
The 52-week high is Rs 375.00 and the 52-week low is Rs 164.45.